Mineralys Therapeutics (MLYS) Return on Capital Employed (2023 - 2026)

Mineralys Therapeutics has disclosed Return on Capital Employed across 4 years of filings, most recently posting 26.69% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 26.69%, up 4877.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 26.69% (up 4877.0% YoY), and the FY2025 annual result was 40.74%, up 4911.0% from the prior year.
• Return on Capital Employed came in at 26.69% for Q1 2026 at Mineralys Therapeutics, up from 27.71% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 16.44% in Q2 2023 to a low of 86.5% in Q4 2024.
• The 4-year median for Return on Capital Employed is 37.5% (2024), against an average of 43.11%.
• Across the five-year window, Return on Capital Employed sank 5319 bps in 2024 and surged 5879 bps in 2025, its largest moves.
• Mineralys Therapeutics' Return on Capital Employed stood at 33.31% in 2023, then sank by 160 bps to 86.5% in 2024, then jumped by 68 bps to 27.71% in 2025, then gained by 4 bps to 26.69% in 2026.
• The last three Return on Capital Employed figures came in at 26.69% (Q1 2026), 27.71% (Q4 2025), and 41.43% (Q3 2025), per Business Quant data.